Peer-reviewed veterinary case report
Dry eye risk in dogs after trimethoprim sulfonamide treatment
By Hardefeldt, Laura Y et al.·Published in Journal of veterinary internal medicine·2026·Melbourne Veterinary School, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Retrospective cohort study on the development of keratoconjunctivitis sicca in dogs treated with trimethoprim sulfonamide: a VetCompass Australia study.
- Species:
- dog
Plain-English summary
A group of dogs treated with a medication called trimethoprim sulfonamide (TMS) was monitored for a common eye condition known as keratoconjunctivitis sicca (KCS), which can cause dry eyes. Out of over 2,200 dogs, only four developed KCS, with an additional 35 showing possible signs of the condition. The study found that the duration and dosage of TMS did not significantly increase the risk of developing KCS, although older dogs and certain breeds were more likely to be affected. Overall, KCS appears to be a rare side effect of TMS treatment in dogs.
People also search for: dog dry eyes treatment · trimethoprim sulfonamide side effects · keratoconjunctivitis sicca in dogs · dog eye problems medication
Abstract
BACKGROUND: Keratoconjunctivitis sicca (KCS) is a common and important eye disease of dogs and has been associated with the administration of trimethoprim sulfonamide (TMS). HYPOTHESIS/OBJECTIVES: Determine the prevalence of KCS after TMS treatment at a population level and describe risk factors for KCS development. ANIMALS: Dogs evaluated in general veterinary practice in Australia with records in VetCompass Australia between 2012 and 2022. METHODS: Natural language processing was used to detect dogs treated with TMS and to detect dogs that subsequently developed KCS. Cox proportional hazards modeling was performed to investigate risk factors such as drug dose, duration of treatment, and patient level characteristics (breed, age, sex). RESULTS: A total of 2243 dogs were treated with TMS during the study period. Four definitive cases of KCS and an additional 35 cases of possible KCS were detected (prevalence 1.8%; 95% confidence interval [CI], 1.3-2.5%). Median duration of TMS treatment was 10 days for both cases (interquartile range [IQR], 7-17 days) and non-cases (IQR, 7-15 days). Median doses were 32 and 33 mg/kg/day for cases and non-cases, respectively. Trimethoprim sulfonamide dose and duration of treatment were not associated with KCS. Some breeds were over-represented and older dogs were more likely to be affected (hazard ratio [HR], 1.076; 95% CI, 1.005-1.152; P = .04). CONCLUSIONS AND CLINICAL IMPORTANCE: Keratoconjunctivitis sicca is rare in dogs treated with TMS.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41742488/